CardioFocus
Date | Investors | Amount | Round |
---|---|---|---|
$2.6m | Series A | ||
$9.6m | Series B | ||
N/A | $10.7m | Early VC | |
N/A | $9.1m | Early VC | |
N/A | $5.9m | Debt | |
N/A | $30.6m | Series C | |
$11.0m | Debt | ||
$2.4m | Debt | ||
N/A | $32.0m | Early VC | |
$8.0m | Debt | ||
N/A | Debt | ||
N/A | $20.2m | Debt | |
$21.0m | Debt | ||
$55.0m | Late VC | ||
* | N/A | $50.0m Valuation: $275m | Late VC |
* | N/A | $15.9m Valuation: $275m | Growth Equity non VC |
* | N/A | $15.9m | Debt |
Total Funding | €181m |
Recent News about CardioFocus
EditCardioFocus, headquartered in Marlborough, MA, specializes in advanced laser technology for the precise treatment of atrial fibrillation (AFib), a type of irregular heartbeat. The company's core product, the HeartLight Endoscopic Ablation System, offers a compliant balloon, direct tissue visualization, and continuous motor-controlled energy delivery, which enhances procedural efficiency and improves patient outcomes. CardioFocus serves healthcare providers, particularly those specializing in cardiac electrophysiology, by offering innovative tools that bring new levels of precision and control to AFib treatment. The company operates in the medical device market and generates revenue through the sale of its specialized ablation systems and related training services. CardioFocus is committed to advancing the science of laser and pulsed field ablation, ensuring durable lesions and successful procedures, thereby optimizing energy delivery across its product portfolio. The company also provides specific training for physicians to ensure the effective use of its systems.
Keywords: atrial fibrillation, laser technology, cardiac electrophysiology, HeartLight, ablation system, procedural efficiency, patient outcomes, medical devices, energy delivery, physician training.